Online citations, reference lists, and bibliographies.
← Back to Search

Side Effects Of Systemic Cyclosporine In Patients Not Undergoing Transplantation.

A. Palestine, R. Nussenblatt, C. Chan
Published 1984 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Twenty-six patients with ocular inflammatory disorders of presumed autoimmune origin were treated with oral cyclosporine. Cyclosporine is a potent T cell regulatory agent that has been utilized extensively in organ transplantation. In general, the patients in this study did not have chronic debilitating illnesses that are observed in organ transplant recipients, did not receive corticosteroids in addition to cyclosporine, and did not undergo any surgical procedure during their treatment. This study describes the observed adverse reactions in this group of patients not undergoing transplantation. The reported side effects of cyclosporine in organ transplant recipients have included nephrotoxicity, hepatotoxicity, infections, lymphoma, hirsutism, gingivitis, and central nervous system toxicity. Side effects were observed that were similar to those in previous reports, but the severity of the nephrotoxicity and hepatotoxicity appeared to be less. Nephrotoxicity occurred in eight patients and hepatotoxicity occurred in one patient. No lymphomas were seen. Hypertension and anemia each were observed in six patients. In addition, previously unreported effects of hyperuricemia, elevated sedimentation rate, and hidradenitis were observed. However, the overall severity of the side effects did not seriously affect the usage of cyclosporine in the patients in this study. Cyclosporine may be useful in the treatment of other autoimmune diseases.
This paper references



This paper is referenced by
10.1161/01.CIR.94.6.1209
Cyclosporine-associated neurotoxicity. The need for a better guide for immunosuppressive therapy.
L. Miller (1996)
10.1093/CLINIDS/11.5.677
Infection and cyclosporine.
J. Kim (1989)
10.1016/S0190-9622(89)70339-X
Cyclosporine in dermatology.
A. Gupta (1989)
10.1161/01.HYP.18.3.334
Renal Changes Associated With Cyclosporine in Recent Type I Diabetes Mellitus
M. Rodier (1991)
10.1111/J.1445-5994.1991.TB01405.X
A randomised double-blind trial of cyclosporin and azathioprine in refractory rheumatoid arthritis.
M. Ahern (1991)
10.1007/BF01649562
Untersuchungen zur Nierenfunktion nierengesunder Patienten unter Ciclosporin
P. Heering (2005)
10.1016/0272-6386(93)70098-J
Hypertension after renal transplantation.
C. Ponticelli (1993)
10.1016/S0025-6196(12)60930-6
Cyclosporine treatment of inflammatory bowel disease.
W. Sandborn (1992)
10.1378/CHEST.88.6.915
Hirsutism: "assessing hair-raising topics".
G. Goldstein (1985)
10.1007/BF03259395
The Mode of Action of Cyclosporin
C. Munro (1990)
10.1038/KI.1988.149
Cyclosporine A enhances vasopressin-induced Ca2+ mobilization and contraction in mesangial cells.
H. Meyer-Lehnert (1988)
10.1046/j.1365-4362.1999.00500.x
The role of salicylic acid in the treatment of psoriasis
M. Lebwohl (1999)
10.1111/j.1572-0241.2001.04111.x
Cyclosporine-induced neurotoxicity during treatment of Crohn's disease: lack of correlation with previously reported risk factors
R. Rosencrantz (2001)
10.1902/JOP.1990.61.2.138
Prolonged systemic administration of cyclosporin A affects gingival epithelium.
S. Pisanty (1990)
10.1038/eye.1990.68
Combination low dose Cyclosporin a and steroid therapy in chronic intraocular inflammation
H. Towler (1990)
10.1038/eye.1989.39
Low dose cyclosporin a therapy in chronic posterior uveitis
H. M. Towler (1989)
10.1136/ard.48.7.550
Assessment of efficacy and acceptability of low dose cyclosporin in patients with rheumatoid arthritis.
M. Dougados (1989)
10.1111/j.1600-0536.1988.tb05510.x
The effect of topical cyclosporin A on the elicitation phase of allergic contact dermatitis
G. W. Cole (1988)
10.1007/978-3-642-70607-3_59
Ciclosporin versus Azathioprine in Rheumatoid Arthritis
Ø. Førre (1985)
10.1002/ANA.410230110
Cyclosporine versus azathioprine in the long‐term treatment of multiple sclerosis—results of the german multicenter study
L. Kappos (1988)
10.1111/j.1365-2362.1987.tb01147.x
Nephrotoxicity of cyclosporin A in humans: effects on glomerular filtration and tubular reabsorption rates
H. Dieperink (1987)
10.1016/0049-0172(92)90046-G
Cyclosporine in rheumatoid arthritis.
B. Dijkmans (1992)
10.1016/0168-8278(92)90123-7
Immunosuppressive therapy for primary biliary cirrhosis.
R. Beukers (1992)
10.1007/978-1-4684-5673-8_48
Hyperuricemia and gout in cyclosporin A-treated renal transplant recipients.
H. Lin (1989)
10.1007/BF00346786
Mononuclear cells infiltrating kidney allografts in the absence of rejection
D. J. Versluis (1988)
10.1007/BF00858649
The pathophysiology of sandimmune (cyclosporine) in man and animals
J. Mason (2004)
10.1016/S0022-5223(19)34421-6
Long-term function of human cardiac allografts assessed by two-dimensional echocardiography.
M. Antunes (1989)
10.1136/ard.49.8.603
Cyclosporin A in psoriatic arthritis: an open study.
K. Steinsson (1990)
10.1007/BF00870373
Renal handling of uric acid under cyclosporin A treatment
P. Høyer (2004)
10.1016/j.jaad.2010.02.062
The use of cyclosporine in dermatology: part II.
C. Ryan (2010)
10.1902/JOP.1999.70.6.587
Clinical effects of periodontal therapy on the severity of cyclosporin A-induced gingival hyperplasia.
A. Kantarcı (1999)
10.1111/j.1346-8138.1991.tb03162.x
Hair Growth on Nude Mice Due to Cyclosporin A
S. Watanabe (1991)
See more
Semantic Scholar Logo Some data provided by SemanticScholar